ACE2 News and Research

RSS

Systemic inflammation triggered by SARS-CoV-2 found to cause human testicular injury

In a new study, a team of researchers demonstrated that testicular injury in humans is not due to direct SARS-CoV-2 infection but more likely is an indirect effect of exposure to systemic inflammation or SARS-CoV-2 antigens.

26 Sep 2022

Resistance of Russian Rhinolophus bats containing ACE2-dependent sarbecoviruses to COVID-19 vaccines

In a new study, researchers investigated the receptor tropism and serological cross-reactivity for spike (S) protein receptor-binding domains from two clade 3 sarbecoviruses found in Russian Rhinolophus (horseshoe) bats.

26 Sep 2022

What is the association between body fat and COVID-19?

Researchers recently assessed the association between adipose tissues and COVID-19 by evaluating autopsy cases and profiling adipose tissue responses to SARS-CoV-2 infections.

26 Sep 2022

A fast and powerful method for the production of SARS-CoV-2 virus-like particles in insect cells

Researchers presented the direct plasmid transfection method for SARS-CoV-2 virus-like particle production in insect cells and applied the VLPs to evaluate the efficacy of monoclonal antibodies and vaccinated donor sera.

26 Sep 2022

Study describes the dynamics of immune responses to triple COVID-19 vaccination

The effectiveness of the three-dose COVID-19 vaccination against SARS-CoV-2 and its variants has been described in detail in a recent study.

23 Sep 2022

Sarbecovirus discovered in Russian bat can infect humans and is resistant to SARS-CoV-2 vaccines

A recently discovered virus in a Russian bat that is similar to SARS-CoV-2, the virus behind COVID-19, is likely capable of infecting humans and, if it were to spillover, is resistant to current vaccines.

22 Sep 2022

Stanford Medicine study shows SARS-CoV-2 can infect human fat tissue

Is SARS-CoV-2 hiding in your fat cells? A study by Stanford Medicine investigators shows that SARS-CoV-2 can infect human fat tissue.

22 Sep 2022

Deep mutational scanning for SARS-CoV-2 Omicron BA.1 and BA.2 subvariants

Researchers performed deep mutational scanning for the SARS-CoV-2 Omicron variant of concern sub-VOC BA.1 and BA.2 receptor-binding domains.

22 Sep 2022

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

In a recent study published in the journal PNAS, researchers from Finland and the United States reported a novel heptad repeat 2 (HR2) peptide that inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without any chemical modifications.

21 Sep 2022

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

In a new study, researchers assessed the efficacy of the scFv76 antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lung damage.

21 Sep 2022

New antiviral mechanism of action for an FDA-approved thiopurine known as 6-thioguanine

Researchers described a novel antiviral mechanism of action for an FDA (food and drug administration)-approved thiopurine known as 6-thioguanine (6-TG).

21 Sep 2022

Prophylactic administration of SARS-CoV-2 specific immunoglobulin Y generated in chicken eggs displays protective effects in infected mice

A new study characterized and tested the antibody activity of SARS-CoV-2-specific immunoglobulin Y (IgY) derived from the eggs laid by chickens immunized with recombinant SARS-CoV-2 receptor binding domain (RBD) protein.

21 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

No adverse affect on sperm quality 6 to 14 months post BNT162b2 COVID vaccine

A study published in the journal Gamete Biology demonstrates that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine developed by Pfizer/BioNTech is not detrimental to sperm health over a long period post-vaccination.

20 Sep 2022

Endogenous exosomes act as decoys for SARS-CoV-2

A recent study published in the journal PLoS Biology discussed exosomes as potential decoys for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

A new study maps the escape mutations found in various strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could cause them to escape neutralization by antibodies or detection by rapid antigen tests that rely on antibody binding for a positive result.

16 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

Research shows a complex relationship between vaping and SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, researchers at the University of California, Riverside investigated the effects of electronic cigarette (EC) use as a risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022